Investigating potential therapeutic targets of amino acid metabolism in temozolomide -resistance and relapse glioblastoma patients

Glioblastoma multiforme (GBM) remains a highly aggressive brain tumor, with temozolomide (TMZ) as the primary chemotherapy agent. However, resistance to TMZ frequently develops in GBM patients, contributing to tumor recurrence
and poor prognoses. Recent studies have implicated the dysregulation of amino acid transport in mediating TMZ resistance. This study focuses on an amino acid transporter that plays a key role in the tumorigenesis and TMZ resistance of GBM. We employed shRNA-mediated knockdown of the amino acid transporter in TMZ-sensitive and TMZresistant GBM cell lines (Pt#3 and Pt#3-R) to evaluate its influence on cell proliferation and migration. Our preliminary data suggest that the knockdown of the amino acid transporter attenuates proliferation in TMZ-resistant GBM cells. These findings point towards the amino acid transporter as a potential therapeutic target to overcome TMZ resistance in GBM.